GPT and lymphopenia: To evaluate if vaccinating patients with newly diagnosed GBMs using CMV-DCs during recovery from therapeutic temozolomide (TMZ)-induced lymphopenia with autologous lymphocyte transfer (ALT) in patients that are seropositive for CMV enhances the T cell response. To evaluate the safety of ALT with CMV pp65-activated T cells in patients with newly diagnosed GBMs during recovery from therapeutic TMZ-induced lymphopenia